1800-272-662
Shopping Cart 0
countryflagAU
Login

Integra LifeSciences Holdings

Healthcare US IART

9.55USD
-0.02(0.21%)

Last update at 2026-03-10T20:00:00Z

Day Range

9.219.78
LowHigh

52 Week Range

22.3646.75
LowHigh

Fundamentals

  • Previous Close 9.57
  • Market Cap2274.95M
  • Volume892669
  • P/E Ratio55.52
  • Dividend Yield-%
  • EBITDA362.60M
  • Revenue TTM1529.60M
  • Revenue Per Share TTM19.35
  • Gross Profit TTM 982.03M
  • Diluted EPS TTM0.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 213.89M 214.68M 93.52M 60.10M 57.40M
Minority interest - - - - -
Net income 180.55M 169.07M 133.89M 50.20M 60.80M
Selling general administrative 616.32M 637.45M 594.53M 687.60M 690.75M
Selling and marketing expenses - - - - -
Gross profit 970.31M 944.64M 851.03M 952.88M 900.95M
Reconciled depreciation 118.30M 16.91M 116.03M 109.46M 110.73M
Ebit 238.92M 197.23M 151.37M 178.98M 122.09M
Ebitda 276.73M 240.19M 192.86M 206.00M 143.25M
Depreciation and amortization 37.81M 42.96M 41.49M 27.03M 21.16M
Non operating income net other 24.57M 67.84M 13.73M 20.30M 11.09M
Operating income 238.92M 197.23M 151.37M 178.98M 111.00M
Other operating expenses 1318.75M 1345.22M 1220.50M 1358.88M 1361.44M
Interest expense 49.59M 50.40M 71.58M 53.96M 64.68M
Tax provision 33.34M 45.60M -40.37200M 9.90M -3.39800M
Interest income 11.92M 6.74M 9.30M 10.78M 2.80M
Net interest income -37.67700M -43.65800M -62.28400M -43.17800M -61.88300M
Extraordinary items - - - - -
Non recurring - - - 64.92M -
Other items - - - - -
Income tax expense 33.34M 45.60M -40.37200M 9.90M -3.39800M
Total revenue 1557.67M 1542.45M 1371.87M 1517.56M 1472.44M
Total operating expenses 731.39M 747.41M 699.66M 794.20M 789.95M
Cost of revenue 587.36M 597.81M 520.83M 564.68M 571.50M
Total other income expense net -25.02600M 17.45M -57.85000M -118.87300M 8.29M
Discontinued operations - - - - -
Net income from continuing ops 180.55M 169.07M 133.89M 50.20M 60.80M
Net income applicable to common shares 180.55M 169.07M 133.89M 50.20M 60.80M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3781.99M 3889.76M 3782.38M 3615.14M 3303.24M
Intangible assets 1067.83M 1126.61M 1145.57M 989.44M 1031.59M
Earning assets - - - - -
Other current assets 100.00M 116.79M 91.05M 231.39M 67.91M
Total liab 2194.10M 2085.36M 2097.58M 2100.27M 1886.50M
Total stockholder equity 1587.88M 1804.40M 1684.80M 1514.87M 1416.74M
Deferred long term liab - 63.34M 45.79M 16.19M 36.55M
Other current liab 176.30M 158.80M 213.11M 182.06M 156.19M
Common stock 0.91M 0.91M 0.90M 0.89M 0.89M
Capital stock 0.91M 0.91M 0.90M 0.89M 0.89M
Retained earnings 946.86M 879.12M 698.57M 532.26M 398.57M
Other liab - 201.84M 135.90M 131.18M 116.11M
Good will 1055.46M 1038.88M 1013.46M 932.37M 954.28M
Other assets - 63.15M 3782.38M 168.60M 27.27M
Cash 276.40M 456.66M 513.45M 470.17M 198.91M
Cash and equivalents - - - - -
Total current liabilities 306.98M 320.91M 340.02M 401.01M 331.31M
Current deferred revenue 8.54M 7.25M 5.29M 5.28M 4.77M
Net debt 1405.28M 1158.70M 1137.84M 1185.24M 1258.91M
Short term debt 29.82M 52.75M 59.77M 159.07M 57.25M
Short long term debt 14.53M 38.12M 45.00M 146.25M 45.00M
Short long term debt total 1681.68M 1615.36M 1651.29M 1655.41M 1457.82M
Other stockholder equity 655.22M 914.12M 1030.49M 1055.77M 1093.68M
Property plant equipment - 311.30M 311.70M 287.53M 337.40M
Total current assets 1058.04M 1161.50M 1153.72M 1237.20M 858.17M
Long term investments - - - - -
Net tangible assets - -361.08700M -474.22700M -406.93600M -569.13500M
Short term investments 32.69M - - - -
Net receivables 259.33M 263.46M 231.83M 225.53M 275.30M
Long term debt 1485.02M 1300.49M 1388.68M 1408.22M 1198.56M
Inventory 389.61M 324.58M 317.39M 310.12M 316.05M
Accounts payable 92.33M 102.10M 61.84M 54.61M 113.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -15.10600M 10.27M -45.15500M -74.05900M -76.40200M
Additional paid in capital - - - - -
Common stock total equity - 0.91M 0.90M 0.89M 0.89M
Preferred stock total equity - - - - -
Retained earnings total equity - 879.12M 698.57M 532.26M 398.57M
Treasury stock - -362.86200M -234.44800M -235.14100M -119.94300M
Accumulated amortization - - - - -
Non currrent assets other 26.01M -510.15100M 16.44M 11.28M 14.64M
Deferred long term asset charges - - - - -
Non current assets total 2723.95M 2728.26M 2628.67M 2377.93M 2445.07M
Capital lease obligations 182.13M 172.04M 105.10M 100.94M 109.76M
Long term debt total - 1300.49M 1388.68M 1408.22M 1198.56M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.91M 0.08M -7.84000M 2.34M 0.91M
Change to liabilities 12.90M 18.76M -60.40100M 12.61M 3.98M
Total cashflows from investing activities -58.58000M -161.44300M -68.07300M -162.66800M -49.70500M
Net borrowings -107.80000M -100.24900M 281.15M -9.20000M -493.83700M
Total cash from financing activities -251.95300M -98.22600M 121.62M 64.46M -180.87200M
Change to operating activities 1.99M -27.37800M 12.48M 24.17M 5.38M
Net income 180.55M 169.07M 133.89M 50.20M 60.80M
Change in cash -56.78700M 43.28M 271.25M 60.07M -36.09700M
Begin period cash flow 513.45M 470.17M 198.91M 138.84M 174.94M
End period cash flow 456.66M 513.45M 470.17M 198.91M 138.84M
Total cash from operating activities 264.47M 312.43M 203.83M 373.68M 199.68M
Issuance of capital stock - - 0.00000M 0.00000M 349.59M
Depreciation 118.30M 119.84M 116.03M 109.46M 110.73M
Other cashflows from investing activities -21.14600M -161.44300M -21.34300M -95.46700M 27.13M
Dividends paid - - 44.56M - -
Change to inventory -29.12400M 5.37M -48.34800M -43.30800M 8.30M
Change to account receivables -33.90500M 7.26M 52.10M -9.42800M -17.02100M
Sale purchase of stock -125.00000M 6.82M -100.00000M 6.95M 358.98M
Other cashflows from financing activities 21.60M 27.27M 766.87M 310.56M 129.54M
Change to netincome 2.19M 126.44M -43.59700M 10.91M 20.14M
Capital expenditures 47.09M 48.08M 63.89M 134.53M 77.74M
Change receivables -33.90500M 7.26M 52.10M -9.42800M -17.02100M
Cash flows other operating 13.55M -0.13600M 38.73M 95.60M 6.49M
Exchange rate changes - - - - -5.20300M
Cash and cash equivalents changes -46.06400M 52.76M 257.38M 60.00M -36.09700M
Change in working capital -39.42000M 18.16M -41.31400M -14.50900M 1.75M
Stock based compensation 27.73M 36.21M 19.59M 21.25M 20.78M
Other non cash items -18.10000M -28.10200M 39.77M 226.32M 13.81M
Free cash flow 217.38M 264.35M 139.94M 239.15M 121.94M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IART
Integra LifeSciences Holdings		 -0.02 0.21% 9.55 55.52 9.94 1.67 1.62 2.56 15.44
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Integra LifeSciences Holdings

1100 Campus Road, Princeton, NJ, United States, 08540

Key Executives

Name Title Year Born
Mr. Jan De Witte Pres, CEO & Director 1964
Ms. Carrie L. Anderson Exec. VP, CFO & Treasurer 1969
Mr. Robert T. Davis Jr. Exec. VP & Pres of Tissue Technologies 1959
Mr. Michael J. McBreen Exec. VP & Pres of Codman Specialty Surgical 1966
Mr. Jeffrey Mosebrook Sr. VP, Principal Accounting Officer & Corp. Controller 1976
Dr. Kenneth E. Burhop Ph.D. Corp. VP & Chief Scientific Officer 1954
Mr. William Compton Chief Information Officer & Corp. VP NA
Mr. Eric Ian Schwartz Exec. VP, Chief Legal Officer & Sec. 1969
Laurene Isip VP of Global Corp. Communications & PR NA
Ms. Maria Platsis Sr. VP of Corp. Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.